Dogs may also experience chronic joint disease if the disease is left untreated. However, the majority of cases of Lyme disease in dogs result in complete recovery with, and sometimes without, treatment with antibiotics. In rare cases, Lyme disease can be fatal to both humans and dogs. References
This article incorporates public domain material from the Centers for Disease Control and Prevention document: "Post-Treatment Lyme Disease Syndrome". Further reading
Ostfeld R (2012). Lyme Disease: The Ecology of a Complex System. New York: Oxford University Press. ISBN 978-0-19-992847-7. Barbour AG (2015). Lyme disease: why its spreading, how it makes you sick, and what to do about it. Baltimore. ISBN 978-1-4214-1721-9. Halperin JJ, ed. (2018). Lyme disease: an evidence-based approach (2nd ed.). Wallingford, Oxfordshire, UK: CABI. ISBN 978-1-78639-207-7. Radolf JD, Samuels DS, eds. (2021). Lyme disease and relapsing fever spirochetes: genomics, molecular biology, host interactions and disease pathogenesis. Poole, UK: Caister. ISBN 978-1-913652-61-6. Oaklander M (17 June 2021). "We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?". Time. External links

Lyme disease organizations at Curlie
CDC - Lyme Disease
Lyme Disease Tests – Lab Tests Online
NIH – Lyme Disease
NICE Guidelines – Lyme Disease
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014. Medical uses
In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults. References
External links
"Peginterferon beta-1a". Drug Information Portal. U.S. National Library of Medicine. Plegridy at the US National Library of Medicine Medical Subject Headings (MeSH)